Clinicopathological and prognostic features of HER2-null and HER2-low advanced breast cancer treated with eribulin or capecitabine.

MLA

Kitadai, Rui, et al. “Clinicopathological and Prognostic Features of HER2-Null and HER2-Low Advanced Breast Cancer Treated with Eribulin or Capecitabine.” Breast Cancer (13406868), vol. 31, no. 6, Nov. 2024, pp. 1037–45. EBSCOhost, https://doi.org/10.1007/s12282-024-01617-y.

APA

Kitadai, R., Shimoi, T., Yazaki, S., Okuma, H. S., Hoshino, M., Ito, M., Saito, A., Kita, S., Kojima, Y., Nishikawa, T., Sudo, K., Noguchi, E., Fujiwara, Y., Yoshida, M., & Yonemori, K. (2024). Clinicopathological and prognostic features of HER2-null and HER2-low advanced breast cancer treated with eribulin or capecitabine. Breast Cancer (13406868), 31(6), 1037–1045. https://doi.org/10.1007/s12282-024-01617-y

Chicago

Kitadai, Rui, Tatsunori Shimoi, Shu Yazaki, Hitomi Sumiyoshi Okuma, Mai Hoshino, Munehiro Ito, Ayumi Saito, et al. 2024. “Clinicopathological and Prognostic Features of HER2-Null and HER2-Low Advanced Breast Cancer Treated with Eribulin or Capecitabine.” Breast Cancer (13406868) 31 (6): 1037–45. doi:10.1007/s12282-024-01617-y.